Navigation Links
Pfizer Commences Its Advertising for Celebrex with All the Warnings

Pfizer manufactures Celebrex and in 2004 the sales of Celebrex was $3.3 billion worldwide. But after widespread concerns about the drug causing heart attacks the company stopped advertising//. But 16 months later the has returned to the consumer ad market in hopes of reviving sales of the drug, which plunged last year during the ad moratorium. Now the new ads feature mixed reactions of warning and also had ingredients that could boost it sales. Each ad includes a boldface warning about the drugs increased chance of inducing a heart attack or stroke that can lead to death.

Dr. Sidney Wolfe, a frequent critic of drug makers said that there is no evidence of any unique benefit with this drug but has a unique risk factor associated with it. Pfizer stopped advertising Celebrex after Merck stopped selling Vioxx, because of its heart dangers. But federal regulators ordered Pfizer to put a so-called black-box warning on Celebrex, detailing its risks and continue selling the drug. Andrew McCormick, a Pfizer spokesman said that all painkillers carry some risk and that the ads disclose Celebrex's potential dangers. Celebrex is far more expensive than the older painkillers, costing about $3 a pill.


'"/>




Page: 1

Related medicine news :

1. Pfizer unveils anti-smoking drug
2. The Effectiveness Of The Breast Cancer Drug By Pfizer
3. New Drug Exubera (Oral Inhaled Insulin) To Be Monitored By Pfizer
4. Erectile Dysfunction Drug Viagra Launched In India By Pfizer
5. Pfizer’s Eraxis Approved By The FD
6. Pfizer Launches Viagra For Lung Disease In UK
7. Pfizer Acquires Worldwide Rights For New Overactive Bladder Drug
8. FDA Approves Pfizer’s Anti-smoking Dru
9. Pfizer vouches safety of long-term inhaled insulin.
10. NICE Setback Rules for Pfizers Inhaled Insulin
11. Patency On Two Drugs From Merck & Pfizer’s To Expire Soo
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/21/2017)... , ... September 21, 2017 , ... ... their communities, nine governmental public health departments have been awarded five-year accreditation status ... mean that the benefits of being served by a PHAB-accredited health department ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... The New ... with autism, announced today the election of Yie-Hsin Hung to the Board of Directors. ... join our Board of Directors. Ms. Hung is an invaluable addition to our team,” ...
(Date:9/21/2017)... ... September 21, 2017 , ... FlipBelt, the fitness brand that specializes ... to the athletic wear market with the launch of their FlipBelt Crops. , The ... essentials securely at their fingertips while at the gym, on the trail, or on-the-go. ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... Prescott, Arizona, is now accredited by The Joint Commission for chemical dependency and ... accredits and certifies U.S. health care organizations that meet the commission’s rigorous standards. ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... voice for people who have kidney disease. The theme “Describe a positive decision ... stories. Entrants needed to meet only one qualification— to have been diagnosed ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... FRANCISCO , Sept. 12, 2017  ValGenesis ... Management Solutions (VLMS), is pleased to announce the ... a member of its Board of Directors and ... ValGenesis VLMS enables life science companies to manage ... the use of paper in this process. Furthermore, ...
(Date:9/9/2017)... , Sept. 9, 2017  Eli Lilly and Company ... and secondary endpoint data for lasmiditan, an investigational, oral, ... demonstrated statistically significant improvements compared to placebo in the ... today at the 18th Congress of the International Headache ... "The data presented today demonstrate lasmiditan,s potential to ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
Breaking Medicine Technology: